X

Trial Profile

CRAFT - Multicenter Experience in Atrial Fibrillation Patients Treated With OAC (CRAFT)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acenocoumarol (Primary) ; Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
Indications Embolism and thrombosis
Focus Therapeutic Use
Acronyms CRAFT

Most Recent Events

30 Aug 2017 Results (n=1904) compare clinical characteristics of real-life AF patients (pts) with pts included in the randomized clinical trials (ROCKET AF and RE-LY), were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
07 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
11 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com